Biblio

Found 243 results
Author Keyword [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2
A. du Bois, Quinn, M., Thigpen, T., Vermorken, J. B., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Neijt, J. P., Oza, A. M., Ozols, R., Parmar, M. K. B., Pecorelli, S., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Stuart, G. C. E., Trimble, E. L., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., and Wagner, U., 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)., Ann Oncol, vol. 16 Suppl 8, pp. viii7-viii12, 2005.
A. du Bois, Quinn, M., Thigpen, T., Vermorken, J. B., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Neijt, J. P., Oza, A. M., Ozols, R., Parmar, M. K. B., Pecorelli, S., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Stuart, G. C. E., Trimble, E. L., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., and Wagner, U., 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)., Ann Oncol, vol. 16 Suppl 8, pp. viii7-viii12, 2005.
A. du Bois, Quinn, M., Thigpen, T., Vermorken, J. B., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Neijt, J. P., Oza, A. M., Ozols, R., Parmar, M. K. B., Pecorelli, S., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Stuart, G. C. E., Trimble, E. L., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., and Wagner, U., 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)., Ann Oncol, vol. 16 Suppl 8, pp. viii7-viii12, 2005.
G. C. E. Stuart, Kitchener, H. C., Bacon, M., du Bois, A., Friedlander, M. Leonard, Ledermann, J. A., Marth, C., Thigpen, T., and Trimble, E. L., 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference., Int J Gynecol Cancer, vol. 21, no. 4, pp. 750-5, 2011.
3
G. C. E. Stuart, Åvall-Lundqvist, E., du Bois, A., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Oza, A. M., Ozols, R., Parmar, M. K. B., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Quinn, M., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Trimble, E. L., Thigpen, T., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., Vermorken, J. B., and Wagner, U., 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration., Ann Oncol, vol. 16 Suppl 8, pp. viii36-viii38, 2005.
G. C. E. Stuart, Åvall-Lundqvist, E., du Bois, A., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Oza, A. M., Ozols, R., Parmar, M. K. B., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Quinn, M., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Trimble, E. L., Thigpen, T., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., Vermorken, J. B., and Wagner, U., 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration., Ann Oncol, vol. 16 Suppl 8, pp. viii36-viii38, 2005.
G. C. E. Stuart, Åvall-Lundqvist, E., du Bois, A., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Oza, A. M., Ozols, R., Parmar, M. K. B., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Quinn, M., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Trimble, E. L., Thigpen, T., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., Vermorken, J. B., and Wagner, U., 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration., Ann Oncol, vol. 16 Suppl 8, pp. viii36-viii38, 2005.
A
A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. , J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.
A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. , J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.
S. M. de Boer, Powell, M. E., Mileshkin, L. R., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. - H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D. M., Hanzen, C., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., and Creutzberg, C. L., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018.
S. M. de Boer, Powell, M. E., Mileshkin, L. R., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. - H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D. M., Hanzen, C., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., and Creutzberg, C. L., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018.
S. M. de Boer, Powell, M. E., Mileshkin, L. R., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. - H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D. M., Hanzen, C., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., and Creutzberg, C. L., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018.
H. C. Kitchener, Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer., Cancer Treat Rev, vol. 31, no. 4, pp. 323-7, 2005.
P. Blake, Swart, A. Marie, Orton, J., Kitchener, H. C., Whelan, T., Lukka, H., Eisenhauer, E., Bacon, M., Tu, D., Parmar, M. K. B., Amos, C., Murray, C., and Qian, W., Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis., Lancet, vol. 373, no. 9658, pp. 137-46, 2009.
J. S. Berek, Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E., Gore, M. E., Grenman, S., Hamilton, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, S. B., Lück, H. J., Lund, B., McGuire, W. P., Neijt, J. P., Ozols, R. F., Parmar, M. K. B., Piccart, M. J., van Rijswijk, R., Rosenberg, P., Rustin, G. J. S., Sessa, C., and Willemse, P. H., Advanced epithelial ovarian cancer: 1998 consensus statements., Ann Oncol, vol. 10 Suppl 1, pp. 87-92, 1999.
J. B. Vermorken, Huinink, W. W. ten Bok, Eisenhauer, E., Favalli, G., Belpomme, D., Conte, P. F., and Kaye, S. B., Advanced ovarian cancer. Carboplatin versus cisplatin., Ann Oncol, vol. 4 Suppl 4, pp. 41-8, 1993.
S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future., Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
F. Trillsch, Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K. H., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schröder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A., Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, Ann Oncol, vol. 25, pp. 1320-7, 2014.
F. Trillsch, Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K. H., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schröder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A., Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, Ann Oncol, vol. 25, pp. 1320-7, 2014.
C
S. Pignata, Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., Cormio, G., Sorio, R., Cavazzini, M. G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M. C., Di Maio, M., Perrone, F., Cancer, M. Italian Tr, Sein, Gd'Investig, Oncology, M. Negri Gyne, Groups, E. Network of, and Investigators, G. Cancer Int, Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, vol. 15, pp. 396-405, 2014.
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.

Pages